CRISPR Therapy and Genetic Disorders
Recent studies and clinical trials show that NTLA-2001 successfully reduced TTR proteins, considered responsible for ATTR (transthyretin amyloidosis). The NTLA-2001 was used in a clinical study, and this gene-editing technology proved to be a success. Intellia Therapeutics and Regeneron Pharmaceuticals’ conducted…